Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK Cells in Chronic Myeloid Leukemia
NCT03348033Phase 2Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous activated and expanded natural killer cells in chronic myeloid leukemia (CML), sponsored by Hospital de Clínicas de Porto Alegre. Status: unknown.
02
Drugs
autologous activated and expanded natural killer cells
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03348033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348033.